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Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) are thought to reduce cancer risk by inhibiting cyclo-oxygenases,
resulting in deceased formation of inflammatory mediators and oxidative stress. We examined whether the level of
one oxidative stress marker, 15-F2t-isoprostane, was affected by NSAID use in plasma and breast nipple aspirate
fluids (NAF) of pre-menopausal women who were participating in a dietary intervention trial (n=121). Baseline
levels of 15-F2t-isoprostane were lower in NSAID users than non-users in both NAF and plasma, although the
differences did not persist after intervention. Over the duration of the study, information on NSAID use was
collected five times, and average 15-F2t-isoprostane levels in both NAF and plasma exhibited a statistically sig-
nificant trend for decreases with increased frequency of NSAID use. These results indicate that NSAID use can
result in lower levels of 15-F2t-isoprostane, which may have implications for the effects of NSAID use on breast
cancer risk.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) use
has been associated with decreased breast cancer risk in
many but not all studies. A review of 14 studies in 2001
indicated that NSAID use might be associated with a
relative risk for beast cancer of 0.82 [1]. Subsequent
studies have either failed to find protective effects or in
contrast have found protective effects that were dose-
dependent [2–8]. NSAIDS also have been suggested to
be useful in treatment of breast cancer [9], warranting
further research on the effects of NSAIDS on the breast.
NSAIDs are thought to exert their cancer-preventive
effects via inhibition of cyclo-oxygenase (COX) en-
zymes, but NSAIDs also can decrease formation of lipid
peroxidation products. Several non-enzymatically
formed arachidonate products were shown to be inhi-
bitable by COX inhibitors in rats [10]. F2-isoprostanes
are formed by non-enzymatic oxidation of arachidonyl-
containing phospholipids, and they have been suggested
to be a marker for the assessment of endogenous oxi-
dative stress levels [11,12]. In humans, 15-F2t-isopros-
tane formation was shown to be decreased by COX-2
inhibitors, although to a more modest extent than other
prostaglandins [13–15]. We previously reported that
15-F2t-isoprostane are present in very high levels in
breast nipple aspirate fluids (NAF) [16,17], and this may
be important since lipid oxidation in the breast has been
shown to be associated with breast cancer risk [18–20].
In this report, we therefore examined whether NSAID
use was associated with decreased 15-F2t-isoprostane
levels in both NAF and plasma.
Methods
The study subjects were 121 healthy premenopausal
(ages 21–50 years) non-smoking women with family
history of breast cancer who participated in the Nutri-
tion and Breast Health Study, a randomized intervention
trial of low fat and high vegetable/fruits diets over a one-
year period [21]. The study was approved by the Human
Investigation Committee of Wayne State University
In this study, fasting venous blood specimens were
obtained at months 0, 3, 6 and 12 and NAF were
collected at 0, 6 and 12 months as described [21,22].
Approximately 60% of the participants were able to
provide NAF specimens. At baseline and every 3 months
thereafter (5 times over 12 months), dietary intake was
assessed by four day food records, body weight was
measured using a Health-o-Meter Professional Beam
Scale, medication use, activity patterns and health in the
2-week period prior to the visit were recorded on a
questionnaire. Average daily energy expenditure values
in metabolic equivalents (MET) were then calculated
based on subject body weight, time spent on each activity
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and published MET values for each activity [23]). Total
15-F2t-isoprostane levels in plasma were measured by a
kit from Cayman Chemical Co. (Ann Arbor, MI) using a
modified Sep-Pak procedure [22,24].
Analysis of covariance [25] was used to calculate and
compare the covariate-adjusted mean 15-F2t-isoprostane
concentrations in plasma and NAF by NSAID use. To
examine a potential dose-response relationship, we com-
puted the number of visits at which NSIAD use was re-
ported as an indicator for regularity or frequency of
NSAID use during the study period. Then, covariate-
adjusted mean 15-F2t-isoprostane concentrations in
plasma and NAF were calculated according to the
cumulative number of visits withNSAIDuse. In addition,
multiple regression analysis was used to assess the linear
relationship between plasma and NAF 15-F2t-isopros-
tane concentrations and the cumulative number of times
of NSIAD use with adjustment for other covariates. In
these analyses means of repeated measurements from all
visits were used for a given individual for all variables
except for the cumulative number of visits with NSAID
use. Number of vegetable/fruit servings per day, total fat
intake (gram/day) and body mass index (weight(kg)/
height(m)2) were included as covariates in these analyses
since they weremajor components of the intervention and
since they were marginally associated with plasma and/or
NAF 15-F2t-isoprostane levels [24]. Age was not included
because there were no associations within the limited age
range of our study population. Plasma and NAF 15-F2t-
isoprostane concentrations as well as continuous inde-
pendent variables were log-transformed (ln) before multi-
variate analysis.
Results and discussion
Users and non-users of NSAIDs did not differ signifi-
cantly by age, body mass index, activity levels in METs,
fat intake, supplement use, race, smoking history, or
history of breast-feeding, except for the prevalence of
respiratory allergies which was higher in single time
users (p=0.009). In NSAID non-users, covariate
adjusted mean levels of 15-F2t-isoprostane tended to
decrease with time on study in both plasma and NAF
Table 1. 15-F2t-isoprostane levels in plasma and nipple aspirate fluid (NAF) by visit and non-steroidal anti-inflammatory drugs (NSAIDs) use
Biospecimen NSAIDs Months
0 3 6 12
No. Meana(SE)b No. Mean(SE) No. Mean(SE) No. Mean(SE)
Plasma No 78 4.80 (0.04) 72 4.71 (0.04) 62 4.81 (0.05) 66 4.70 (0.04)
Yes 42 4.69 (0.06) 29 4.68 (0.06) 34 4.63 (0.06) 31 4.67 (0.07)
p-value – 0.102 – 0.615 – 0.028 – 0.706
NAF No 35 10.18 (0.21) – – 30 9.77 (0.19) 35 9.66 (0.18)
Yes 29 9.42 (0.24) – – 22 9.79 (0.22) 18 9.68 (0.27)
p-value – 0.020 – – – 0.946 – 0.962
a Units are pg/ml for plasma 15-F2t-isoprostane and pg/g for NAF 15-F2t-isoprostane, adjusted for total fat intake/day, number of fruit and
vegetable servings/day and body mass index. All variables in the model except NSAID use were log-transformed.
b Standard error (SE).
Table 2. Mean plasma and nipple aspirate fluid (NAF) 15-F2t-isoprostane levels over 12 months of study by reported number of occurrences of
non-steroidal anti-inflammatory drugs (NSAIDs) use
No. of occurrence of NSAIDs use Biospecimen
Plasma NAF
No. Meana (SE)b No. Mean (SE)
0 51 4.80 (0.04) 20 10.17 (0.21)
1 22 4.78 (0.06) 13 9.68 (0.25)
2 17 4.69 (0.07) 13 9.37 (0.26)
3 14 4.72 (0.08) 7 9.42 (0.38)
4 12 4.54 (0.08) 7 9.49 (0.37)
5 4 4.68 (0.15) 4 10.01 (0.50)
p-values for liner trend – 0.013 – 0.033
a Units are pg/ml for plasma 15-F2t-isoprostane and pg/g for NAF 15-F2t-isoprostane, adjusted for total fat intake/day, number of fruit and
vegetable servings/day and body mass index. All variables in the model except NSAID use were log-transformed.
b Standard error (SE).
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(Table 1). Since 75% of the women were randomized to
intervention diets, this suggests that intervention effects
might be stronger in NSAID non-users. Levels in
NSAID users were lower than that in NSAID users at
baseline, and this was significant in NAF. At later time
points, the 15-F2t-isoprostane levels in NAF were very
similar in NSAID users and non-users. This was partly
due to 24 subjects who dropped out during intervention
period. In plasma the lower levels in NSAID users
persisted up to 6 months, indicating that levels in
plasma do not necessarily predict levels in NAF
(Table 1).
The impact of frequency of NSAID use was examined
over 12 months of study, and average 15-F2t-isoprostane
levels decreased with frequency of NSAID use reported
at each of the five study visits (Table 2). Levels were
higher in both plasma and NAF for women who
reported NSAID use at all five visits relative to women
who reported NSAID use at four visits, but only four
women used NSAIDs at all five visits. The trend for
increasing occurrence of NSAID use and lower levels of
15-F2t-isoprostane was statistically significant for both
plasma and NAF (Table 2). The decrease in NAF is
especially noteworthy since the NAF composition may
indicate what breast ductal cells are exposed to. These
results indicate that NSAID use can result in lower levels
of 15-F2t-isoprostane in breast NAF, which may one
mechanism by which NSAID use can decrease breast
cancer risk.
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